BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 19016004)

  • 1. Blood coagulation and fibrinolysis in patients with acromegaly: increased plasminogen activator inhibitor-1 (PAI-1), decreased tissue factor pathway inhibitor (TFPI), and an inverse correlation between growth hormone and TFPI.
    Erem C; Nuhoglu I; Kocak M; Yilmaz M; Sipahi ST; Ucuncu O; Ersoz HO
    Endocrine; 2008 Jun; 33(3):270-6. PubMed ID: 19016004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels.
    Erem C; Nuhoglu I; Yilmaz M; Kocak M; Demirel A; Ucuncu O; Onder Ersoz H
    J Endocrinol Invest; 2009 Feb; 32(2):169-74. PubMed ID: 19411818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism.
    Erem C; Kocak M; Nuhoglu I; Yilmaz M; Ucuncu O
    Eur J Endocrinol; 2009 May; 160(5):863-8. PubMed ID: 19233920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alterations of haemostatic and fibrinolytic markers in adult patients with growth hormone deficiency and with acromegaly.
    Sartorio A; Cattaneo M; Bucciarelli P; Bottasso B; Porretti S; Epaminonda P; Faglia G; Arosio M
    Exp Clin Endocrinol Diabetes; 2000; 108(7):486-92. PubMed ID: 11083070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
    Erem C
    Clin Endocrinol (Oxf); 2006 Mar; 64(3):323-9. PubMed ID: 16487444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hypothyroidism.
    Erem C; Ucuncu O; Yilmaz M; Kocak M; Nuhoglu I; Ersoz HO
    Endocrine; 2009 Feb; 35(1):75-80. PubMed ID: 18958631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood coagulation and fibrinolysis in male patients with hypogonadotropic hypogonadism: plasma factor V and factor X activities increase in hypogonadotropic hypogonadism.
    Erem C; Kocak M; Hacihasanoglu A; Yilmaz M
    J Endocrinol Invest; 2008 Jun; 31(6):537-41. PubMed ID: 18591887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood coagulation, fibrinolysis and lipid profile in patients with primary hyperparathyroidism: increased plasma factor VII and X activities and D-Dimer levels.
    Erem C; Kocak M; Hacihasanoglu A; Yilmaz M; Saglam F; Ersoz HO
    Exp Clin Endocrinol Diabetes; 2008 Nov; 116(10):619-24. PubMed ID: 18484067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hyperthyroidism.
    Erem C; Ucuncu O; Yilmaz M; Kocak M; Nuhoglu İ; Ersoz HO
    Endocrine; 2009 Dec; 36(3):473-8. PubMed ID: 19859836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults.
    Johansson JO; Landin K; Johannsson G; Tengborn L; Bengtsson BA
    Thromb Haemost; 1996 Sep; 76(3):422-8. PubMed ID: 8883281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anomalies of lipoprotein pattern and fibrinolysis in acromegalic patients: relation to growth hormone levels and insulin-like growth factor I.
    Wildbrett J; Hanefeld M; Fücker K; Pinzer T; Bergmann S; Siegert G; Breidert M
    Exp Clin Endocrinol Diabetes; 1997; 105(6):331-5. PubMed ID: 9439928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood coagulation and fibrinolysis in patients with hyperthyroidism.
    Erem C; Ersoz HO; Karti SS; Ukinç K; Hacihasanoglu A; Değer O; Telatar M
    J Endocrinol Invest; 2002 Apr; 25(4):345-50. PubMed ID: 12030606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor and thrombomodulin levels in children with hypothyroidism.
    Alioğlu B; Kılıç N; Şimşek E; Dallar Y
    J Clin Res Pediatr Endocrinol; 2012 Sep; 4(3):146-50. PubMed ID: 22985614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood coagulation, fibrinolysis and lipid profile in patients with prolactinoma.
    Erem C; Kocak M; Nuhoglu I; Yılmaz M; Ucuncu O
    Clin Endocrinol (Oxf); 2010 Oct; 73(4):502-7. PubMed ID: 20039901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coagulation parameters and platelet function analysis in patients with acromegaly.
    Colak A; Yılmaz H; Temel Y; Demirpence M; Simsek N; Karademirci İ; Bozkurt U; Yasar E
    J Endocrinol Invest; 2016 Jan; 39(1):97-101. PubMed ID: 26048595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship among TAFI, t-PA, PAI-1 and F1 + 2 in type 2 diabetic patients with normoalbuminuria and microalbuminuria.
    Chudý P; Kotuličová D; Staško J; Kubisz P
    Blood Coagul Fibrinolysis; 2011 Sep; 22(6):493-8. PubMed ID: 21519232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levels of factor VIIc associated with decreased tissue factor pathway inhibitor and increased plasminogen activator inhibitor-1 in dyslipidemias.
    Zitoun D; Bara L; Basdevant A; Samama MM
    Arterioscler Thromb Vasc Biol; 1996 Jan; 16(1):77-81. PubMed ID: 8548430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue factor pathway inhibitor and other endothelium-dependent hemostatic factors in elderly individuals with normal or impaired glucose tolerance and type 2 diabetes.
    Leurs PB; Stolk RP; Hamulyak K; Van Oerle R; Grobbee DE; Wolffenbuttel BH
    Diabetes Care; 2002 Aug; 25(8):1340-5. PubMed ID: 12145232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lower androgenicity is associated with higher plasma levels of prothrombotic factors irrespective of age, obesity, body fat distribution, and related metabolic parameters in men.
    De Pergola G; De Mitrio V; Sciaraffia M; Pannacciulli N; Minenna A; Giorgino F; Petronelli M; Laudadio E; Giorgino R
    Metabolism; 1997 Nov; 46(11):1287-93. PubMed ID: 9361687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibrinolysis inhibitors in plaque stability: a morphological association of PAI-1 and TAFI in advanced carotid plaque.
    Jönsson Rylander AC; Lindgren A; Deinum J; Bergström GM; Böttcher G; Kalies I; Wåhlander K
    J Thromb Haemost; 2017 Apr; 15(4):758-769. PubMed ID: 28135035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.